So far, no results on clinical studies for the usage of these compounds in AD have been released (the first data of the phase 2 study on CY6463 are expected in July 2022; ClinicalTrials.gov Identifier: NCT04798989), but the preclinical studies show a great potential for sGC activators in AD treatment (Figure 3). This evidence concerns the gene SGCB and Alzheimer disease.